Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Earnings call · FY2025 Q4
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Management tone
Confident
Net tone +72 · low hedging
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hello, and welcome to the GenMAP Full Year 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans, or expects. Actual results may differ materially, for example, as a result of delays or unsuccessful development projects. GenMAP is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note, GEMMAP may hold your personal data as indicated by you as a part of our Investor Relations Outreach activities in order to update you on GEMMAP going forward. Please refer to our website for more information on GEMMAP and our privacy policy. I would like to hand the conference over to our first speaker today, Jan van der Winkle. Please go ahead.
Hello and welcome to our Financial Results Call for 2025. With me today is our Chief Financial Officer Anthony Pagano and our Chief Commercial Officer Brad Bailey. For the Q&A, we will be joined by our Chief Medical Officer Tanya Mahdi and our Chief Development Officer Judith Klimovski. As noted, we will be making forward-looking statements, so please keep them in mind. As we reflect on 2025, I would like to remind you of the commitments that we made at the beginning of the year. We said that we would accelerate the development of our high-impact late-stage pipeline, that we would maximize the potential of our commercialized medicines, and that we would deliver on our capital allocation priorities. I'm pleased to say that we have delivered on these commitments. And we begin 2026 with a diversified, high-quality revenue base and a late-stage portfolio that can drive sustainable growth well into the 2030s. In 2025, we grew total revenue by 19%, fueled by both our royalty portfolio and sales from our own medicines. And we also invested fully aligned with our capital allocation priorities. Importantly, we have also grown operating profit, even while making these strategic investments. 2025 was marked by some significant milestones in our mission to deliver innovative medicines to patients. Highlights include positive momentum for Epkinli as it continues to demonstrate the potential to become a core therapy in B-cell lymphomas, its FDA approval in second-line follicular lymphoma in combination with R-squared, as well as the unprecedented data in this indication, are key milestones. Taken together, these move treatment into earlier lines of therapy and expand our impact for people living with follicular lymphoma. We also build on our commitment to the Guinong community. In addition to the availability of TIFDEC in both Japan and Europe, we expanded the development of RINA-S, ending the year with three phase three trials across PROC, endometrial cancer, and PSOC. Finally, a pivotal step on our journey to sustainable diversified growth was our acquisition of Meris. It's enhanced our late-stage portfolio with P2 Centumab. With P2 Centumab joining at Kindy and RINA-S, we have a strong pipeline of late-stage assets that will provide us with multiple value-creating catalysts in 2026 and in the future. Now, let's take a look at the strength of these three programs on the next slide. With our five combined breakthrough therapy designations, these three programs have multi-billion dollar potential, and they firmly underpin our long-term growth. Epkinli is currently the only bispecific antibody with a dual indication across B-cell malignancies in the U.S., Europe, and Japan. And following unprecedented data, Epkinli plus R-squared is well positioned to become a best-in-class option in second-line plus follicular lymphoma. RINA-S is a folate receptor alpha-targeted ADC designed to broaden the visibility beyond high expressors. Based on current expression distributions, this could expand the addressable PROC population by as much as three times versus approved medicines that are restricted to high folate receptor alpha expression. And finally, P2-centromop, a potentially transformative EGFR-LGR5 bispecific antibody with compelling data in both first-line and later-line recurrent and metastatic head-and-neck cancer. As a reminder, in the first-line setting, P2Centamop, in combination with PEMBRO, achieved a 63% response rate, and that is more than three times higher than the 19% that has been observed at the standard of care. 2026 will be a defining year for all three of these programs, as we will see on the next slide. We expect up to six potentially registrational data results that could set the stage for multiple important product launches and line extensions in 2027. In the second half of the year, we expect phase 2 data for RINA-S in platinum-resistant ovarian cancer. We also anticipate that one or both phase 3 trials for P2-centromop in first and second line or third line head and neck cancer will deliver top-line data in the second half. And while we anticipate around 25,000 potential patients for later lines of therapy in first-line head-and-neck cancer, this increases to an additional 41,000 patients. For Hapkinli, we anticipate data from two Phase III trials in diffuse lab B-cell lymphoma. The indication with the largest addressable patient population, around 70,000 people, is of course front-line diffuse lab B-cell lymphoma. And we are looking forward to data in this indication in combination with our CHOP this year. We are also looking forward to data in the first half of the year in second line plus diffuse last piece of lymphoma in combination with linalidamides. Now, as you are aware, in January we announced top line results from the phase 3 APCOR-DL-BCL1 trial of a Kindly monotherapy. The results showed an improvement in progression-free survival, as well as improvements in complete response rate, duration of response, and time-to-next treatments. And in fact, this is the first phase 3 study to demonstrate an improvement in progression-free survival in patients with relapsed or refractory diffused LAS B-cell lymphoma who are treated with a CD3, CD20 T-cell engaging bispecific monotherapy. Overall survival did not reach statistical significance, and further analysis of the data is ongoing, including the potential impact of a variety of factors, including COVID-19, and the increasing availability of novel antilymphoma therapies. The full trial results will be submitted for presentation at a future medical meeting, and we will engage with global regulatory authorities on next steps. The monotherapy results do not change our expectations for our other phase 3 trials. And we are very confident that these studies continue to have the potential to move Epkinly earlier in the treatment paradigm and significantly increase its addressable population from approximately 27,000 patients today to almost 150,000 patients by early in the next decade. The data presented across Abkinli, RINA-S, and Patrocentomob in 2025 strengthened our conviction in these programs. Now, in 2026, it is the meaningful registrational readouts that will be the catalyst that allow us to potentially bring these antibodies to patients in 2027. I'm pleased to now hand you over to Brad for a review of the recent commercial performance for Abkinli and TIFTAC.
Thanks, John. 2025 marked another successful year for our commercialization team. We maintained leading positions for our proprietary brands globally, and we made important progress evolving into a wholly owned model, fueling our long-term growth engine. In the past year, we successfully executed four key launches across our portfolio, two of which were led entirely by GenMap, demonstrating the strength of the commercialization model we built in the US, Japan, and now in Europe. We expanded our footprint to three additional markets, opening business operations in Germany, the UK, and France, and we delivered on our commitment to bringing our antibody-based medicines to patients in areas of high need. To this end, CIVDAC became the first ADC approved in recurrent or metastatic cervical cancer in the EU, UK, and Japan, providing a much needed option for patients whose disease progresses after initial therapy and where outcomes have historically been poor. Additionally, with its approval in the U.S. and relapsed refractory follicular lymphoma, McKinley became the first bispecific antibody approved in any form of non-Hodgkin's lymphoma in the second-line setting, and the first bispecific combination therapy approved in the lymphoma space. These milestones represent progress for patients, and they set the foundation for our growth trajectory in gynecologic cancers, along with RNA-S in the future, and further into B-cell malignancies. Through our efforts in 2025, sales of our proprietary medicines totaled $632 million. This is up 54% year-over-year and accounting for approximately 28% of our total revenue We expect this growth trajectory to continue in 2026, grounded in the strong foundation we've built as we deliver our own medicines to an increasing number of patients around the world. Now let's take a closer look at Epkinly. We closed out 2025 with solid performance, achieving $468 million in sales for the year, which represents a 67% year-over-year increase. This performance was driven by continued growth for the brand across geographies as the first and only bispecific with approved dual indication in diffuse large B-cell diploma and FL in Europe, Japan, and the US. In fact, Epkinlee closed 2025 with regulatory approvals in more than 65 countries, nearly all of which feature the dual indication. We continue to be encouraged by Epkinle's strong momentum and the positive feedback we hear from physicians across geographies regarding Epkinle's differentiated clinical profile, powerful efficacy, and proven safety, and the value of having a single dual-indication option across DLVCL and FL. In the U.S., this momentum's translated to continued growth for Epkinle across sites of care with an acceleration in new sites ordering including in the community and the majority of health systems now ordering from multiple sites as expected following the launch of epkinley and second line fl in november we're seeing increased uptake suggesting that this approval will be a growth driver for the brand in japan we continue to see epkinley's launch in third line plus fl build on the brand success and large b-cell lymphoma this is driven in large part by Epkinle's dual indication differentiation and execution by our field teams to activate sites. Across all other markets, we continue to increase our presence through our partner, AbbVie, and its global footprint. We closed out the year with yet another quarter of solid sales for Epkinle in these markets as we continue to see rapid uptake in countries gaining access and reimbursement. Looking ahead, 2026 will be a pivotal year for Epkinle as we advance our position in early lines of therapy and anticipate key data readouts supporting Epkinle's versatility and status as the core therapy in B-cell malignancies. Our focus is on delivering Epkinle to as many patients as possible, particularly in early lines of therapy where we see the market opportunity, and critically, where we may have the opportunity to truly transform the trajectory of these diseases for patients. To that end, we're maximizing our first mover advantage and second line FL in the U.S., And we expect to build on this opportunity across markets with anticipated approvals in this setting in Europe and Japan later this year. With this traction and earlier lines of FL, we're looking towards key readouts in 2026 in first and second line DLBCL with fixed duration Epkinley combination therapies to further strengthen Epkinley's position in DLBCL. Together with a robust development program for Epkinle and strong execution by our teams, we see a clear opportunity for Epkinle to achieve blockbuster status over the next few years. Moving now to TIBDAC. TIBDAC continues to be recognized as the global standard of care in recurrent or metastatic cervical cancer. In 2025, TIBDAC generated $164 million in sales, representing a 26% year-over-year increase. TivTac continues to form well across both new and established markets, highlighting the clear need for treatments that improve survival for women with advanced cervical cancer across geographies. In the U.S., notably, TivTac posted its fourth consecutive year-over-year growth, underscoring its continued market leadership. This strong, stable performance continues to be driven by the depth and breadth of sites of care using TIBDAC. In Japan, TIBDAC demonstrated another strong quarter of continued performance, underscoring the traction it's gaining in the second-line setting and the high patient need in recurrent and metastatic cervical cancer in the country. This trend continued in Europe for the launch in Germany continues to be off to an encouraging start with strong, consistent uptake and positive physician feedback. As the first medicine we've launched in Europe independently, our efforts in recent months have demonstrated our ability to strategically build infrastructure and scale in new markets. We received MHRA approval in December in the UK and are now working towards reimbursement to bring TIBDAC to more patients as soon as possible. As we look ahead to the new fiscal year, we have the foundation in place to continue this momentum and bring TIBDAC to additional markets. Infrastructure and operations are well underway in new markets while our team's executing in preparation for exciting launches on the horizon. We expect to see continued positive performance across markets as we strengthen and scale our presence and broaden our impact within the gynecologic cancer community. Wrapping up, 2025 was a critical year in our company's evolution. We built on our proven launch expertise and scientific strength and achieve key milestones to solidify our commercialization model and business operations that will unlock our ability to deliver on the significant growth opportunities ahead of us. Our proven ability to evolve our model in the U.S. and Japan, coupled with the early traction we are seeing in Europe, gives us the confidence that we have the pieces in place today to drive future growth and expansion. With this strong foundation, 2026 is shaping up to be another meaningful year for GenMAP. We will grow the impact of our proprietary portfolio, expand our footprint, and strengthen our capabilities as we look toward entering new and larger market opportunities and delivering on the blockbuster potential of Epkinly, Rhena S, and Peter Sintimab in the coming years. With that, I'll hand the call over to Anthony to discuss our financials.
Thanks, Brad. 2025 was a year of strong execution for GenMAP. With solid revenue growth, expanding profitability, and disciplined investment. Looking ahead, our 2026 guidance reflects the same framework we outlined at Q3 and at the time of the Meris acquisition. And it also reflects our continued commitment to funding growth while maintaining substantial profitability. Now, before diving into the numbers, please note that the results and guidance This I will review exclude the impact of acquisition-related expenses, including amortization. A reconciliation to our reported results is included in the appendix. In 2025, total revenue increased 19% to $3.7 billion, reflecting strong execution across our royalty portfolio, as well as continued progress for our commercialized medicines. We also continue to improve the quality of our revenue profile with a higher contribution from our own medicines, especially at Kinley, further diversifying our revenue base. In addition, we strengthened our long-term growth potential with the addition of pedocentumab to our late-stage pipeline. Alongside the Merit Acquisition, we made targeted strategic investments during the year with operating expenses up 13%. The investments we made in building our commercialization capabilities are already delivering for us today. And importantly, they are positioning us to support expansion into earlier lines throughout Kinley and the potential launches of RENA-S and Pitocentumab in 2027. And even with these investments, we expanded operating profit to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales. Overall, 2025 demonstrates the strength and quality of GenMAP's underlying financial performance. Turning to our 2026 guidance, our framework is straightforward. Revenue growth enables strategic investment which supports long-term value creation. At the midpoint, we expect 14% total revenue growth driven by continued momentum in F. Kinley and our royalty portfolio, further enhancing revenue quality. More specifically, we expect Darzilek's net sales in the range of $15.6 billion to $16.4 billion. As discussed previously, expectations for operating expenses were in a reasonable place. For 2026, the increase in operating expenses reflects planned investments to advance late-stage development for pedosentimab and RENA-S, as well as launch readiness activities to support multiple potential product launches. Even with the strategic step-up, our guidance delivers on our commitment to maintain substantial profitability in 2026. With that, now I would like to provide some context for how revenue growth supports a deliberate increase in investments while delivering $1.15 billion of operating profit at the midpoint for 2026. And you can see this on the chart on the right. What really stands out is the strength of our underlying business, demonstrated by strong organic operating profit growth before our planned investments in Pedocentimax. Here, we are choosing to reinvest part of the operating leverage now to strengthen future growth drivers while continuing to manage costs actively and maintain profitability discipline. This balance, reinvesting to support growth while driving substantial profitability is a core feature of our operating model. Taken together, our 2025 results and 2026 guidance demonstrate consistent delivery against our financial commitments. Our capital allocation framework remains fully aligned with our strategy to drive sustainable growth well into the 2030s. First, we will continue to invest to accelerate our late-stage pipeline and maximize the success of our commercialized medicines, including launch readiness. These investments are intended to generate meaningful revenue for us in the future. Second, we will continue the rapid integration of Meris to accelerate value capture while maintaining focus and prioritization. And third, we remain committed to deleveraging, targeting gross leverage below three times by the end of 2027, maintaining balance sheet strength and flexibility. In summary, our performance in 2025 underscores our ability to deliver revenue growth, our ability to advance key pipeline assets, and our ability to maintain strong profitability through disciplined execution. Looking ahead to 2026, we are building on this momentum through disciplined prioritization of our investments, continued operating discipline, and expansion of market opportunities. This positions us for sustained growth and long-term value creation. And on that note, I'm going to hand you back over to Jan.
Thank you, Anthony. Our confidence in our ability to execute on key data retails in 2026 and subsequent high-impact launches in 2027 come from our track record. We have proven that we are excellent evaluators of innovation and that we deliver on our promises. We have also proven that we are disciplined in our execution against our capital allocation framework and in the prioritization of our investments. And we are committed to delivering profitable growth. Genwop is a skilled oncology biotech business with strong momentum, an increasingly diversified growth profile, and multiple catalysts ahead. As we begin 2026, our focus remains on translating our antibody science and development expertise into meaningful breakthroughs for patients and long-term value for shareholders. That ends our formal presentation. Thank you for listening.
Operator, please open the call for a question. thank you so much dear participants as a reminder if you wish to ask a question please press star one one on your telephone keypad and wait for your name to be announced to withdraw a question please press star one and one again to ensure everyone has the opportunity to ask a question today please limit yourself just to one question thank you so much for your understanding please tambour will compile the q and a q these will take a few moments and now we're going to take our first question. And it comes to the line of Jonathan Chang from Lyrinc. Your line is open. Please ask your question.
Hi, guys. Thanks for taking my questions. Can you discuss what the next steps are for Epkinli following the results of the EPCOR-DLBC1 study? Can you still get the second line plus label with the EPCOR-DLBC4 combination study? And what was the rationale, I guess, behind using the monotherapy DLB-CL1 study as the confirmatory study in the first Thank you.
Thanks, Jonathan, for the questions. I will hand it over to Thay to explain in further detail what the next steps are for the regulatory part for O5. Thay?
Yeah, thank you, Jan, and thank you, Jonathan, for the question. Yes, as we already indicated in the press release, I mean, the O5 study is positive this by PFS as a single agent beating a chemo-immuno regimen on progression pre-survival, but it missed the overall survival, confounded by key aspects that are already discussed in the community. One is being COVID. The study was involved heavily during the Omicron wave. And the other one is the emergence of access to biospecifics, of which we are an important part as well. So we'll have this discussion with the agencies. There are pre-specified analysis in the protocol that were already agreed prior to the readout on these two major biases. And so we'll have this conversation both with the FDA and, of course, with the European health authorities and global health authorities on the data set. And we're also going to have this conversation with you guys once it is in the public domain. As it relates on the rationale for – which was your third question – on the rationale for why this is the confirmatory study, It's important to put yourself back into the situation where we were, when this APINI program started, this was the first phase three to be initiated, and hence it was a confirmatory study because the requirement for an accelerated approval is that you have a confirmatory study initiated and really actually well enrolled by the time you file for the accelerated approval, which is why this was initially, while it was for a long time, the only diffuse search research study. the confirmatory study discussions are ongoing with the agencies about all the other uh phase three studies that we have are ongoing too specifically for which we both are already guided that we will have a readout this year um there is absolutely from our end and no indication from any of the health authority interaction uh any readout to the fiability of the um other study that has been conducted and that we already guided will read out the first half of this year which is the combination with LEN-EPCO in second line, third line. This is a separate study that was set up separately. This was started and initiated after the Omicron wave. It is testing a combination regimen with lenalidomide with a fixed duration, as Brad was saluting to earlier. So it's a different study with different opportunities. And we'll be looking forward to have this data in our hand and to also communicate them to the community and then to engage with health authorities as a public.
Thanks, Ty. Jonathan, I think that answers your question then, huh?
Jonathan Wittman- Understood. Thank you very much.
Jonathan Wittman- Let's move to the next. Oh, yes, of course. The next question comes from from is open. Please ask a question.
Thanks for taking my question. So you presented EPCO outpatient data late last year. Just want to get an update from you on how this data has been adapted to change in the the practice in the U.S., I guess given, maybe can give us an idea of what proportion of community clinics that are still sending patients to, the obesity patients to a large center to get that step up dose monitoring. And then just maybe to tag on to Jonathan's question, could you put us at ease and just tell us what you think is the likelihood that you'll be able to convince the regulatory agencies to consider one of the many other EPCO phase three study readouts that are coming this year as a confirmatory study.
Thanks, Asika, for the questions. I will first hand it over to Tai, and then also Brad will definitely be able to comment on the community, the central use of APCO, I believe. But Tai, why don't you start with the first question?
Yeah, I mean, thank you. I should go with this question. So I'm going to reiterate the degree, but reaffirm what I said earlier. We have, at this point, three phase threes in Diffuse Archbisa. One, that we already announced the results, and then two, that we already announced we're going to have the results this year, one in the first half at least, and the other one we have not committed to. So we are extremely comfortable to a degree also by the precedent already said on the Glow-Free program, but also generally speaking, that this is really not a concern on our end in terms of the confirmation trial. Anyway, we have two major phase threes that are really not. In addition to a study that was positive on PFS but confounded on OS. So this is, as much as I can say at this point, we are not concerned about this. And don't see a reason to be concerned. So if you look at the precedent that was set by Rush. On the outpatient, I'll leave it to Brad to talk about the pattern of prescription. But what I would say to the outpatient study is that that was an important strategy for a variety of reasons. One is, of course, what will Brad talk about, practice patterns in the community. But it's also an incredibly important component for our overall regulatory strategy to modify the label and to have labor language that then also facilitates administration of activity in the community. And Brad, you can take it from here.
Yeah, no, just to have telling off that, you're absolutely correct. And we do see this as certainly an enabler, if you will, and as we continue to evolve and receive physician feedback, specifically moving into even earlier, more early lines of therapy, see this as a potential, a great opportunity.
Thanks, Brad. Thanks, Ty. Let's move on to the next question. Thank you, Astica.
Thank you. Now we're going to take our next question. And it comes to the line of Xian Deng from UBS. Your line is open. Please ask a question.
Hi, Xian from UBS. Thank you very much for taking my question. So I have one on Rina S, please. So given the pivotal phase two that's due to come out this year, and given this is kind of pivotal phase two and there it's not a formal phase three so just wondering what determines when you can decide you are going to have a readout you know what is the definition of this because i guess here you don't have to have a you know the formal pfs here and it's an open label trial so that's the first question and then and then sorry the second ones are just a very quick yes and no question please so for fkingly frontline dlbcl trial I'm just wondering, can you confirm whether you have passed the interim, please? Thank you.
Well, thanks, Sion, for the question. The first one, I will ask Judith to address, and then Ty can give a very short answer on the second question. Judith, why don't you start on the phase two data for Rina?
Yes, thank you for the question. So, the study was designed or the pivotal arm with a potential outcome of being supportive of accelerated approval, and accelerated approval is a path that the FDA has for drugs when the results support with the substantial benefit over current standard of care with endpoints that can predict substantial benefit. So the way the Phase II design is, is for ORR and duration of response, a validated endpoint clinical benefit. The validity of approval is also dependent on having Phase III's. We have...
Thank you, Judith. And then maybe, Ty, can you get some color on the front line if you start this on a former study?
Thank you for the question, and I appreciate the attempt of a yes-no question. But we're just going to reiterate what we've been saying publicly since J.P. Morgan, that we expect the reader for the study to have.
Thanks, Ty. Thanks, Ian, for the questions.
Thank you. Now we're going to take our next question. And the question comes line of Rajan Sharma from Goldman Sachs. Your line is open. Please ask the question.
Hi. Thanks for taking my question. So just same with Kinley. Could you just discuss your expectations into the APCOR DLBCL4 trial? What do you think is a clinically meaningful outcome here, especially relative to LUNCEMIO and MPoliby?
Thanks for the question. Ty, can you address the DLBCL4 question?
What I mean, the anticipation is that it will actually be a trial that will be registered, which is the first differentiation to the studies that you mentioned. That's, I think, the intent. And it's a study that has a, as I said, combination with an aridomide that was involved exclusively after the Amiton wave, which was a significant confounder for a lot of the studies that were run with these by-specifics in the diffuse archivist space, not only the diffuse archivist, but relevant to this conversation. And we're really excited and looking forward to this data set, which will also have a larger portion of a second-line patient. And so the expectation is that this is a trial that will be positive and then will lead to registration in the second and third time.
Thanks, Ty. Thanks, Christian, for the question. Let's move on to the next one.
Thank you so much. And now we're going to take our next question from Judah from Morgan Stanley. Your line is open. Please ask a question.
Yeah, hi. Thanks for taking the question, guys. I was just curious on your thoughts on the Pembro approval in P-ROC recently and kind of implications for Renna S. And then maybe just more high-level, we appreciate the guidance on Darzal X, but I guess just kind of given positive data in combo with Biospecific at Ash, just curious if you have any kind of high-level thoughts on the Darzal X trajectory over the coming years, maybe versus where your expectations were, you know, six, 12 months ago for that trend.
Thanks, Judith. Judith, can you start, and then maybe Ty can chip in?
Yeah, thank you. Thank you for the question. So we are aware of the data and the approval. I think it's a good potential option for patients. However, two things not to underestimate. First, that the approval is in PD-L1 positive, CPS1 above 1%, and this encompasses around 70% of the population, and B, the combination includes weekly taxol, which is not minor for patients. So on the one hand, it is great that patients have another option. On the other hand, we believe that RINA can be more transformative and serve the full, broad population.
Thanks, Judith. I think that addresses your question, Judith. So let's move on to the next one.
Thank you. The next question comes from James Gordon from Parkway. If your line is open, please ask a question.
Hello, James Gordon from Barclays. Also a question on that Kinley in first-line DLBCL. So my question was, what are you hoping to see when the trial reports in terms of the OS benefit? Would you hope to see a strong OS benefit, even though it is the first-line trial, and some other agents like Pilevy had struggled to do that, and I know that related to the lack of OS benefit? And then sort of connected to it, just what is the efficacy bar? Are you just hoping to be static? Would you need to be materially better than Pilevy, Pilarix, given that Rush to doing a CD3, CD20 on top of it, maybe also just like support someone to use the front-line trial as well in terms of whether that's any sort of bar.
Thank you, James, for the questions. This is definitely Thay questions and very exciting questions. So let's see what Thay answers them.
All right, let's try my best to answer your questions in sequence. I think the first part that I think we've been very clear for a while is that the primary endpoint is PFS. the expectation on our end the anticipation and the excitement is that we believe that in combination with Usher will be transformative of course the data will have to show we've been arguing for a while that the robust phase 2 data sets have been quite informative in our development on the second line for the conformer just to remind everybody again the phase 3 mimicked almost to a point the efficacy that we had seen in the second line data set in combination with N-square, R-square, and second-line for the conformer. And if you then go back and revisit the data that's in the public domain on R-shop in combination with the kidney and IPI 3 to 5, in particular, pay attention to the CR, which is the most relevant data point. So there is a reason, and this is where the excitement, the enthusiasm, the expectation comes from our end, to believe that the study will be quite positive. Now, I'm not going to speculate on what positive really, really means, but certainly on a compound-by-compound, we anticipate that it's going to exceed the currently reported Phase III data sets that are positive. As it relates to OS, you're absolutely right, in Diffuse HB-SERA OS is an endpoint that lags to a degree also by a change on practice, but also because of the impact on PFS. So I think this is a discussion we can have once we have the data set, and we can have a conversation on the scale of improvement in PFS and how that translates to us.
Thanks, thanks, Ty. I think we have to leave it with that, but that was a very good answer. Thanks, Jane, for the question. Let's move on to the next question.
Thank you so much. And the next question comes to the line of Zane Abrahim from GDP.
Morgan your line is open please ask a question thank you Morgan thanks for taking my question a quick clarification question on it clearly just in the first time deal BCL trial in terms of the events tracking houses how they're tracking relative to your expectations given reiteration of this 2026 as opposed to sort of narrowing it down to the first half and then my actual question was on the nearest acquisitions following the acquisition and completion, have you spoken to the FDA about the trial design for the ongoing phase three trials, and based on those conversations, how confident you are that objective response rate is sufficient as a regulatory endpoint?
Thanks, Sian, for the question. So we'll ask Ty to talk a bit about events tracking, if we can, and then Judith can potentially address the PITO question on trial design in Head & Head Council. So, Ty, why didn't you start?
On events tracking, I don't necessarily think this is what we do in calls like this, that we give a commentary on events tracking.
So, we cannot comment.
So, this is not something that we can do right now. But we obviously do track them.
All right, thanks. Then let's move on to Judith and then maybe some feedback on the design of the HEDRNEC pivotal trials for PETO.
Yeah, no. Thank you for the question. As we all know, I mean, the two phase three studies have a dual endpoints ORR and OS, which I would say, as you know, the Origami 5 recently published has as well ORR and PSS. So it's quite a standard that in areas of unmet medical need, the FDA and even other health authorities can be prone to earlier endpoints associated with more overall survival. So we feel good with the dual endpoints that both studies have. And, of course, you know, as part of the integration, we are digging into the operational characteristics of the studies. But we are pleased with the design as is, the dual endpoint.
Thank you, Judith. Thanks, Ayn, for the questions. Let's move on to the next one.
Thank you so much. And the next question comes from Suzanne Balberhuizen from Van Lanshot Company. Your line is open. please ask your question.
Hi, team. This is Suzanne from Kempen. Thanks for taking my question. I was wondering for Pito whether we should be expecting a Phase 1-2 data update in head and neck cancer during this year at a medical conference, considering especially the frontline data set for the matured since ASCO last year. This could be very insightful for the market ahead of the Phase 3 readouts. And if there is a data update, could you elaborate what but you believe the expectations should be on duration metrics and survival, for example. Thank you.
Thanks, Suzanne, for the questions. I will ask Judith to comment on that. Suzanne, as you know, we hope to see one or both of the Phase III data this year, that you asked specifically about the Phase I-II data.
Yeah, no, thank you for the question. I want to reinforce that the last readout for the PITO-PEMBRO combination was with around 15-month follow-up, which allowed to see 79% of patients at 12-month landmark overall survival. And so, of course, there is censoring, but the censoring happened after the 12-16 months, which is what you expect from the control arm. So, what I'm trying to say is that the last ASCO 2025 presentation from MERUS is very informative in terms of the probability of success of the phase three, and you can take advantage of that presentation, I'm ready.
Thank you, Joda. Thanks, Suzanne, for the question. Let's move on to the next one.
Thank you. And our next question comes to the line of Jaren Werbe from TD Security. If your line is open, please ask the question.
Thank you so much. So, quick question, just as a natural follow-up. The Origami 5 study, as you mentioned, uses Kichudan chemo as a combo, presumably in patients with more ebolicly aggressive disease and frontline. Would you consider doing the same sort of child design with PDO?
Judith, can you address that question from Jaren on Aligam if you want?
Yeah, no, thank you for the question. So first, let me know that we are behind the original strategy, which is combining PITO with PEMBRO. And the reason is that the 65% ORR, furthermore with 60Rs, is unprecedented, even in the context of what we know for PEMBRO chemo. So, we are very pleased that MEDUS put in place a strategy that could offer a chemo-free option for patients. Having said that, given the data that you have seen and we have seen on PITO, we believe that the CDP potentially could be expanded on many different directions. This could be one, but we are very – we think that the chemo-free combinations for patients that can offer almost double what the chemo can offer is a very good value proposition for patients.
Thanks, Yaron, for the questions. Some more to come.
Thank you. And our next question comes line of Kiza Ding from Rothschild & Co. Your line is open. Please ask your question.
Hi, guys. Thanks for taking my question. So I noticed that the PETO sentiment is at phase two stage for combining temporal supermap in first-line non-small cell lung cancer. Just wanted to clarify, is this a new trial that was started in Q4 2025? If so, could you please share your high-level thoughts and expectation behind this study?
Thanks, Kisa, for the question. Judith, can you comment on the lung cancer trial for PETO?
Yeah, yeah, I can. thank you. So as we all know, you know, EGFR is a good target for lung cancer. The study was planned as a signal seeking in the indications where cetuximab showed the maximum benefit, and in combination with PEMBRO, given that what we know, which is the synergy between PETO and PEMBRA. So it's a signal-seeking study and we will update you when we have data.
Thanks. Thanks, Kiesa, for the question. Let's move on to the next one.
Thank you. And the next question comes from Matthew Phipps from William Blair. Your line is open. Please ask a question.
Thank you for taking my question. Just to confirm, you list an additional phase three for PETA in 2026. Is that the locally advanced trial that you've already talked about or something else? And do you anticipate providing any update from the colorectal cancer cohorts that we saw in the fall or maybe thoughts on the development plan there? Thank you.
Thank you, Matt, for the question. So, Yulet, maybe you can address both of them.
Yeah, thank you. Thank you for the question. So, yeah, the data that Merus presented did in December on colorectal was very encouraging. I'll rate a limited number of patients. As it was shown publicly, each one of the cohorts is to enroll 40, 40, and 60. So this data set is growing, and as the data is growing, we plan to inform the medical community, and We have not decided when, but the data set is growing. And in terms of future phase 3s, we already mentioned the locally advanced head and neck, and we are actively working on a comprehensive clinical development plan.
Thanks, Jolanda. Thanks, Matt, for the question.
Thank you. And now we're going to take our next question, and it comes to line of Victor Floch from BNP Paroiba. Jolanda is open. Please ask your question.
Hi. Thanks so much for taking my question, Victor. Thank you, Paribas. So maybe a quick one on the pipeline and, I mean, most specifically your early-stage pipeline, which has been, you know, significantly streamlined over the last 12 months. And to my knowledge, only contends now to Kinkah stage by specific. So I just want to, you know, hear your thoughts and maybe whether you can discuss your priorities moving forward in terms of platform technologies and therapeutic areas. I can't really, like, see any ADCs, so maybe it's, I mean, whether you can discuss, like, what are the technologies behind the two recent INDs you've done, but so, you know, moving forward, whether you can discuss whether you believe you have enough candidates in-house, or should we expect also some early-stage M&A at some point? Thanks so much.
Victor, let me start off here, and then I can definitely chip in. We've recently actually had three IND findings, one for a biospecific antibody, one for an ADC, making use of the linker and payload technology which we acquired via Perfone Bio, and one which is a biospecific also including the hexabody technology. So when you look at our whole pipeline overall, 45% is ADC right now, So 50% is dual-body-based, so bi-specific-based, and 5% hexabody-based, Victor. But right now we are integrating both the MIRIS pipeline and the Genma pipeline and only prioritize the high-impact ones, basically, for further development. So we have a very, I think, diversified pipeline, all based on next-generation antibody technologies. But I will stop here, and maybe Thay can give you a bit more color on the organic pipeline, which is still a key priority for the company to actually fill the pipeline with candidates which can then be promoted to mid- and late-stage programs in due time. Thay?
Yeah, I mean, you're kind of like famous already, right? So as you said, when we have three INDs that we found towards the end of the year with, you know, that are all expecting dosing this month. More to come on this end in this year as well. And our focuses are now particularly also after the integration of the mails and the capabilities that came to that integration continue to be in antibodies and then they fall into these categories of next-generation ADC platforms, which is an increased interest of our research in SUZU, and next-generation bi-specific and tri-specific platforms. There is obviously a focus on our research capabilities in Utrecht, and that's what we're going to continue to do. There is, of course, a change now with a very heavily focused late-stage landscape within Gemma, with PETO being positioned in head and neck, and maybe we'll see in the future also opportunities in colorectal, with rena being positioned in the gynon space and ovarian endometrial, but also maybe possibly based on data, also opportunities in other foreign receptor alpha tumors, there is very clearly also a change on how we think internally about where our focus should be. So it's not completely a disease area focus, but without a doubt we're starting to get into a space where we're also starting to think about combinatorial strategies for our internal asset. But generally speaking, you should expect more to come from our internal capabilities. And that in and of itself does not preclude that we will not continue to look for external innovation, because that's what we're going to do.
Thanks, Diana. I think Victor will need to do that. Thanks, Victor. Yeah, thanks so much.
Thank you. Now we're going to take our next question. And the question comes line of Matthias Habblom from Handel's Backend. Your line is open. Please ask your question.
Thanks so much. I had one on P2, an asset which you now own. Help me think about what you need in terms of additional information from ongoing or future clinical trials to specify your current peak sales potential from multi-billion dollar to an actual number like you have for Red King and RIN S. Thanks so much.
Thanks, Matthias, for the question. And I will hand it over with pleasure to Anthony Pagano to see what he's willing to say about the multibillion-dollar potential of these molecules.
Yeah, thanks, Matthias. As you've heard from us since the time of the acquisition, we're highly encouraged by the data we've seen so far for pedocentumab, highly encouraged by the outside in recognition from the SBA in terms of the breakthrough therapy designations, and really looking forward here to one or more data readouts, pivotal readouts, during the course of 2026, and equally looking forward to potentially expanding into earlier lines in terms of starting a first phase three in locally advanced head and neck cancer. So, if we look at this overall, pedosymptomab has the characteristics of potentially being best in class, first in class, And we're really focused on expanding, accelerating it to also make it broadest in class, starting, of course, in head and neck cancer. For now, we're going to remain with our guidance in terms of multi-billion blockbuster potential. As we continue to review the opportunity, refine our CDP, see more data, we'll look for the right time to update that. So, I'm not going to front run this, Matthias, in terms of guiding to when we're going to potentially update guidance. But the key takeaway here really is that we're very happy owners of Pedocentimac, and we look forward to seeing the data later in 2026 and continue to expand and accelerate the CDP.
Thanks, Anthony. We will leave it to this, Matthias, but thank you for the question.
Thank you. And now we're going to take our next question, and it comes to line of Sarah B. from Guggenheim Your line is open. Please ask your question.
Hi, this is Sarah. I'm from Michael Schmidt from Guggenheim. Thanks for taking my question. I wanted to quickly circle back to VINAS, if you could comment on the size of the opportunities for VINAS, both in and outside of Dynon, including in the ongoing phase two. And then separately, super quickly, if you could clarify the terms of the debt offering announced late last year. Thank you.
Thank you, Sarah. Antonike, you addressed both questions, the size of the opportunity for RENA and also the debt offering terms.
Sure. Happy to do so. First of all, everything I've just said about pitocentamab, I would echo for RENA-S. very happy owners of RENA-S, and the team is really here looking for any and all opportunities to expand and accelerate the opportunity. Again, looking forward to the first potentially pivotal and registrational data here during the course of 2026, initially in the platinum-resistant ovarian cancer setting. Today I can reiterate our overall guidance of $2 billion plus for RENA-S. That's really underpinned by second line plus PROC, second line plus endometrial, second line plus PSOC, and then also, moving forward, the frontline endometrial opportunity. What's important to note, for those first three indications that I've mentioned, second line PROC, second line endometrial, second line PSOC, we've already initiated phase three trials. So, very excited about the opportunity. Very excited about what we're seeing in terms of the data so far, both in PROC and endometrial cancer. So, that takeaway is we continue to reiterate our PQR sales guidance of $2 billion plus, and a very significant amount of clinical development work is ongoing to underpin that investment, that PQR sales guidance, excuse me. In terms of the overall debt offering, first of all, we're very pleased with the demand for the offering, both in quantum in terms of also the high-quality nature of the investors that ultimately subscribe to the deal. Again, it's $5.5 billion with roughly $2.5 billion of it being fixed. Another $3 billion is floating rate debt based upon a spread over three months so far. Now, what we have done for the $3 billion that is floating around $1.6 billion of that, we've hedged back to make it fixed. So net $4.1 billion is now fixed as well as the remaining being floating. One thing I would leave you with is that we've committed and remain committed to getting below three times gross leverage by the end of 2027. And one maybe other data point to kind of help you sort of think this through would be, if you look at the kind of weighted average, you know, based on current market conditions, the weighted average sort of effective interest rate of the debt is around 6.6%.
So that's what I can help you guys for now.
Thanks, Anthony. Thanks, Sarah, for the questions. Let's see whether there's any further questions. Operator?
Now we're going to take our last question for today. And it comes to the line of Benjamin Jackson from Jefferies. Your line is open. Please ask the question.
Brilliant. Thank you. A bunch of the times for just one from me. I guess longer term, are you able to comment on how you're thinking about the level of sales and marketing investments needing to be made ahead of any potential launches, given that you're now starting to get into the later stages, a lot of this pivotal data. So how comfortable are you with how big and where the team is located today and how much more scale needs to be achieved in terms of feet on the floor? Thank you.
Thanks, Ben, for the question. And I will ask Brad to give a short feedback here.
Yeah, thank you for the question. And we continue to be disciplined on OPEX as guided, and certainly we'll invest strategically to strengthen the development and commercialization to bring our medicines to as many patients as possible. We're strong with where we are today, both U.S. and Japan, and early signs in Europe are encouraging, and I look forward to sharing more in the not-too-distant future.
Thanks. Thanks, Brad. So more to come, Ben, in the future. Thank you.
Thank you, Benjamin. There are no further questions for today. I would now like to hand the conference over to your speaker, Jaban Zerbinkel, for any closing remarks.
Jaban Zerbinkel Thank you for calling in today. If you have additional questions, please reach out to our investor relations team. We very much look forward to speaking with you again soon.
Jaban Zerbinkel This concludes today's conference call. Thank you for participating. Imanel, all disconnect. Have a nice day.
24:44 to 1:00:59 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Hi, guys. Thanks for taking my questions. Can you discuss what the next steps are for Epkinli following the results of the EPCOR-DLBC1 study? Can you still get the second line plus label with the EPCOR-DLBC4 combination study? And what was the rationale, I guess, behind using the monotherapy DLB-CL1 study as the…
Jan van de Winkel: Thanks, Jonathan, for the questions. I will hand it over to Thay to explain in further detail what the next steps are for the regulatory part for O5. Thay?
Also speaking: Tahamtan Ahmadi
Thanks for taking my question. So you presented EPCO outpatient data late last year. Just want to get an update from you on how this data has been adapted to change in the the practice in the U.S., I guess given, maybe can give us an idea of what proportion of community clinics that are still sending patients to, the…
Jan van de Winkel: Thanks, Asika, for the questions. I will first hand it over to Tai, and then also Brad will definitely be able to comment on the community, the central use of APCO, I believe. But Tai, why don't you start with the first question?
Also speaking: Tahamtan Ahmadi, Brad Bailey
Hi, Xian from UBS. Thank you very much for taking my question. So I have one on Rina S, please. So given the pivotal phase two that's due to come out this year, and given this is kind of pivotal phase two and there it's not a formal phase three so just wondering what determines when you can decide you are going to have…
Jan van de Winkel: Well, thanks, Sion, for the question. The first one, I will ask Judith to address, and then Ty can give a very short answer on the second question. Judith, why don't you start on the phase two data for Rina?
Also speaking: Judith Klimovsky, Tahamtan Ahmadi
Hi. Thanks for taking my question. So just same with Kinley. Could you just discuss your expectations into the APCOR DLBCL4 trial? What do you think is a clinically meaningful outcome here, especially relative to LUNCEMIO and MPoliby?
Jan van de Winkel: Thanks for the question. Ty, can you address the DLBCL4 question?
Also speaking: Tahamtan Ahmadi
Yeah, hi. Thanks for taking the question, guys. I was just curious on your thoughts on the Pembro approval in P-ROC recently and kind of implications for Renna S. And then maybe just more high-level, we appreciate the guidance on Darzal X, but I guess just kind of given positive data in combo with Biospecific at Ash…
Jan van de Winkel: Thanks, Judith. Judith, can you start, and then maybe Ty can chip in?
Also speaking: Judith Klimovsky
Hello, James Gordon from Barclays. Also a question on that Kinley in first-line DLBCL. So my question was, what are you hoping to see when the trial reports in terms of the OS benefit? Would you hope to see a strong OS benefit, even though it is the first-line trial, and some other agents like Pilevy had struggled to…
Jan van de Winkel: Thank you, James, for the questions. This is definitely Thay questions and very exciting questions. So let's see what Thay answers them.
Also speaking: Tahamtan Ahmadi, Speaker 5, Judith Klimovsky
Hi, team. This is Suzanne from Kempen. Thanks for taking my question. I was wondering for Pito whether we should be expecting a Phase 1-2 data update in head and neck cancer during this year at a medical conference, considering especially the frontline data set for the matured since ASCO last year. This could be very…
Jan van de Winkel: Thanks, Suzanne, for the questions. I will ask Judith to comment on that. Suzanne, as you know, we hope to see one or both of the Phase III data this year, that you asked specifically about the Phase I-II data.
Also speaking: Judith Klimovsky
Thank you so much. So, quick question, just as a natural follow-up. The Origami 5 study, as you mentioned, uses Kichudan chemo as a combo, presumably in patients with more ebolicly aggressive disease and frontline. Would you consider doing the same sort of child design with PDO?
Jan van de Winkel: Judith, can you address that question from Jaren on Aligam if you want?
Also speaking: Judith Klimovsky
Hi, guys. Thanks for taking my question. So I noticed that the PETO sentiment is at phase two stage for combining temporal supermap in first-line non-small cell lung cancer. Just wanted to clarify, is this a new trial that was started in Q4 2025? If so, could you please share your high-level thoughts and expectation…
Jan van de Winkel: Thanks, Kisa, for the question. Judith, can you comment on the lung cancer trial for PETO?
Also speaking: Judith Klimovsky
Thank you for taking my question. Just to confirm, you list an additional phase three for PETA in 2026. Is that the locally advanced trial that you've already talked about or something else? And do you anticipate providing any update from the colorectal cancer cohorts that we saw in the fall or maybe thoughts on the…
Jan van de Winkel: Thank you, Matt, for the question. So, Yulet, maybe you can address both of them.
Also speaking: Judith Klimovsky
Hi. Thanks so much for taking my question, Victor. Thank you, Paribas. So maybe a quick one on the pipeline and, I mean, most specifically your early-stage pipeline, which has been, you know, significantly streamlined over the last 12 months. And to my knowledge, only contends now to Kinkah stage by specific. So I just…
Jan van de Winkel: Victor, let me start off here, and then I can definitely chip in. We've recently actually had three IND findings, one for a biospecific antibody, one for an ADC, making use of the linker and payload technology which we acquired via Perfone Bio, and one which…
Also speaking: Tahamtan Ahmadi
Thanks so much. I had one on P2, an asset which you now own. Help me think about what you need in terms of additional information from ongoing or future clinical trials to specify your current peak sales potential from multi-billion dollar to an actual number like you have for Red King and RIN S. Thanks so much.
Jan van de Winkel: Thanks, Matthias, for the question. And I will hand it over with pleasure to Anthony Pagano to see what he's willing to say about the multibillion-dollar potential of these molecules.
Also speaking: Anthony Pagano
Hi, this is Sarah. I'm from Michael Schmidt from Guggenheim. Thanks for taking my question. I wanted to quickly circle back to VINAS, if you could comment on the size of the opportunities for VINAS, both in and outside of Dynon, including in the ongoing phase two. And then separately, super quickly, if you could…
Jan van de Winkel: Thank you, Sarah. Antonike, you addressed both questions, the size of the opportunity for RENA and also the debt offering terms.
Also speaking: Anthony Pagano
So that's what I can help you guys for now.
Jan van de Winkel: Thanks, Anthony. Thanks, Sarah, for the questions. Let's see whether there's any further questions. Operator?
Brilliant. Thank you. A bunch of the times for just one from me. I guess longer term, are you able to comment on how you're thinking about the level of sales and marketing investments needing to be made ahead of any potential launches, given that you're now starting to get into the later stages, a lot of this pivotal…
Jan van de Winkel: Thanks, Ben, for the question. And I will ask Brad to give a short feedback here.
Also speaking: Brad Bailey